Cargando…
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
BACKGROUND: Although pancreatic ductal adenocarcinomas (PDAs) widely express HER2, the expression level is generally low. If HER2 expression in PDA cells could be enhanced by treatment with a given agent, then combination therapy with that agent and trastuzumab emtansine (T-DM1), a chemotherapeutic...
Autores principales: | Kan, Shin, Koido, Shigeo, Okamoto, Masato, Hayashi, Kazumi, Ito, Masaki, Kamata, Yuko, Komita, Hideo, Nagasaki, Eijiro, Homma, Sadamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609140/ https://www.ncbi.nlm.nih.gov/pubmed/26475267 http://dx.doi.org/10.1186/s12885-015-1772-1 |
Ejemplares similares
-
Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016) -
Regulation of Tumor Immunity by Tumor/Dendritic Cell Fusions
por: Koido, Shigeo, et al.
Publicado: (2010) -
Immunologic Monitoring of Cellular Responses by Dendritic/Tumor Cell Fusion Vaccines
por: Koido, Shigeo, et al.
Publicado: (2011) -
In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells
por: Koido, Shigeo, et al.
Publicado: (2008) -
Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions
por: Koido, Shigeo, et al.
Publicado: (2013)